| (Values in U.S. Thousands) | Nov, 2025 | Aug, 2025 | May, 2025 | Feb, 2025 | Nov, 2024 |
| Sales | 13,580 | 7,890 | 44,060 | 18,450 | 13,280 |
| Sales Growth | +72.12% | -82.09% | +138.81% | +38.93% | +5.48% |
| Net Income | -78,220 | -86,420 | -43,460 | -56,350 | -58,550 |
| Net Income Growth | +9.49% | -98.85% | +22.87% | +3.76% | -19.59% |
Nurix Therapeutics Inc
(NRIX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.
Fiscal Year End Date: 11/30